FIELD: medicine.
SUBSTANCE: composition includes glutaryl histamine in an amount of 18.0-75.0 wt % as an active substance, and as auxiliary substances: microcrystalline cellulose in an amount of 18.0-71.0 wt %, sodium croscarmellose in an amount of 0.25-1.0 wt %, colloidal silicon dioxide in an amount of 0.5-2.0 wt %, calcium stearate in an amount of 0.5-2.0 wt % and lactose monohydrate. The invention also relates to a method of obtaining the said composition.
EFFECT: invention is characterised by the high bioavailability of the active component and high pharmacological activity.
4 cl, 6 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TABLETTED PHARMACEUTICAL COMPOSITION AND METHOD FOR PRODUCING IT | 2013 |
|
RU2539375C1 |
| PHARMACEUTICAL COMPOSITIONS BASED ON N-CARBAMOYL-METHYL-4-PHENYL-2-PYRROLIDONE | 2012 |
|
RU2560691C2 |
| DOSAGE FORM CONTAINING DESLORATADINE AND METHOD FOR PRODUCING IT | 2013 |
|
RU2550958C2 |
| PHARMACEUTICAL COMPOSITION FOR SLEEP DISORDERS PREVENTION AND TREATMENT | 2016 |
|
RU2620855C1 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING DORAVIRINE, TENOFOVIR DISOPROXIL FUMARATE AND LAMIVUDINE | 2016 |
|
RU2736941C2 |
| PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING MENTAL, BEHAVIOUR AND COGNITIVE DISORDERS | 2012 |
|
RU2488388C1 |
| PHARMACEUTICAL COMPOSITIONS OF MONTELUCAST AND LEVOCETIRISINE | 2013 |
|
RU2677649C2 |
| NEW COMPOSITION OF LAPATINIB AS A SOLID DOSAGE FORM FOR ORAL USE AND A METHOD OF ITS MANUFACTURE | 2019 |
|
RU2821950C2 |
| NEBIVOLOL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, METHOD OF PRODUCING SAID SALTS AND NEBIVOLOL PHARMACEUTICAL COMPOSITIONS | 2005 |
|
RU2378272C2 |
| FORMULATIONS OF AZAINDOLE COMPOUNDS | 2014 |
|
RU2685730C1 |
